The Asia Pacific overactive bladder treatment market is expected to grow from US$ 871.48 million in 2022 to US$ 1,082.25 million by 2028; it is estimated to grow at a CAGR of 3.7% from 2022 to 2028.
Robust Pipeline of Drugs and Successive Launch of Novel Therapies to Bolster Asia Pacific Overactive Bladder Treatment
In December 2020, a new drug application was approved for Gemtesa, a beta 3-agonist and a novel treatment for overactive bladder in adults. Gemtesa (vibegron), provided by Urovant Sciences, helps in relaxing the detrusor bladder muscle, which enables the bladder to hold more urine; the relaxation of this muscle reduces overactive bladder symptoms. It is a once-daily pill and the first overactive bladder medication that does not require dose titration. Many universities and academic institutions are conducting robust research and development activities on novel molecules to treat OAB. For instance, the Yonsei University College of Medicine and Severance Hospital, Seoul, South Korea, is evaluating DA8010, a novel muscarinic M3 receptor antagonist. In September 2021, the university published that in the phase 2 trial, the M3 antagonist DA8010 was demonstrated for the efficacy and safety of overactive bladder treatment. The robust pipeline of drugs for overactive bladder treatment and the successive launch of novel drugs and therapies are expected to drive the growth of the Asia Pacific overactive bladder treatment market in the coming years.
AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Asia Pacific overactive bladder treatment market.
Robust Pipeline of Drugs and Successive Launch of Novel Therapies to Bolster Asia Pacific Overactive Bladder Treatment
In December 2020, a new drug application was approved for Gemtesa, a beta 3-agonist and a novel treatment for overactive bladder in adults. Gemtesa (vibegron), provided by Urovant Sciences, helps in relaxing the detrusor bladder muscle, which enables the bladder to hold more urine; the relaxation of this muscle reduces overactive bladder symptoms. It is a once-daily pill and the first overactive bladder medication that does not require dose titration. Many universities and academic institutions are conducting robust research and development activities on novel molecules to treat OAB. For instance, the Yonsei University College of Medicine and Severance Hospital, Seoul, South Korea, is evaluating DA8010, a novel muscarinic M3 receptor antagonist. In September 2021, the university published that in the phase 2 trial, the M3 antagonist DA8010 was demonstrated for the efficacy and safety of overactive bladder treatment. The robust pipeline of drugs for overactive bladder treatment and the successive launch of novel drugs and therapies are expected to drive the growth of the Asia Pacific overactive bladder treatment market in the coming years.
Asia Pacific Overactive Bladder Treatment Market Overview
The Asia Pacific overactive bladder treatment market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. The market growth is attributed to the rising geriatric population, increasing urinary incontinence cases, and a growing number of product launches. Overactive bladder is caused due to abdominal trauma, urinary infection, urinary incontinence, and nerve damage. According to National Centre for Biotechnology (NCBI), in 2019, 1 in 5 individuals above 40 years was identified with symptoms of overactive bladder syndrome in China. The Chinese Medical Journal stated that the rate of overactive bladder cases was 5.9% among people over 18 years in 2019. According to World Health Organization, people aged 60 years in China are expected to grow from 10% in 2021 to 28% by 2041. Further, as per the World Population Aging 2019, in Hong Kong, people aged 60 years and older accounted for 17.5% of the total population in 2019. With the growing geriatric population, the number of patients having an overactive bladder and urinary tract infection is expected to increase in the coming years. All these factors are contributing to the Asia Pacific overactive bladder treatment market growth.Asia Pacific Overactive Bladder Treatment Market Segmentation
The Asia Pacific overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.- Based on pharmacotherapy, the Asia Pacific overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the Asia Pacific overactive bladder treatment market in 2022.
- Based on disease type, the Asia Pacific overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.
- Based on country, the Asia Pacific overactive bladder treatment market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.
AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Asia Pacific overactive bladder treatment market.
Table of Contents
1. Introduction1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Overactive Bladder Treatment Market- By Pharmacotherapy
1.3.2 APAC Overactive Bladder Treatment Market- By Disease Type
1.3.3 APAC Overactive Bladder Treatment Market - By Country
2. APAC Overactive Bladder Treatment Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Overactive Bladder Treatment Market - Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.3 Expert Opinion
5. APAC Overactive Bladder Treatment Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of Urinary Incontinence
5.1.2 Growing Incidence of Urinary Tract Infections
5.2 Key Market Restraints
5.2.1 Recalls of Therapeutic Drugs
5.3 Key Market Opportunities
5.3.1 Increasing Number of Mergers and Acquisitions
5.4 Future Trends
5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
5.5 Impact analysis
6. Overactive Bladder Treatment Market - APAC Analysis
6.1 APAC Overactive Bladder Treatment Market Revenue Forecast and Analysis
7. APAC Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy
7.1 Overview
7.2 APAC Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
7.3 Mirabegron
7.3.1 Overview
7.3.2 Mirabegron: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.4 Botox
7.4.1 Overview
7.4.2 Botox: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.5 Neurostimulation
7.5.1 Overview
7.5.2 Neurostimulation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.3 Transcutaneous Sacral Nerve Stimulation
7.5.3.1 Overview
7.5.3.2 Transcutaneous Sacral Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.4 Transcutaneous Tibial Nerve Stimulation
7.5.4.1 Overview
7.5.4.2 Transcutaneous Tibial Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
7.5.5.1 Overview
7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.6 Others
7.5.6.1 Overview
7.5.6.2 Others: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Anticholinergics
7.6.1 Overview
7.6.2 Anticholinergics: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.3 Solifenacin
7.6.3.1 Overview
7.6.3.2 Solifenacin: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.4 Oxybutynin
7.6.4.1 Overview
7.6.4.2 Oxybutynin: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.5 Fesoterodine
7.6.5.1 Overview
7.6.5.2 Fesoterodine: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.6 Darifenacin
7.6.6.1 Overview
7.6.6.2 Darifenacin: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.7 Tolterodine
7.6.7.1 Overview
7.6.7.2 Tolterodine: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.8 Trospium
7.6.8.1 Overview
7.6.8.2 Trospium: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.9 Other Anticholinergics
7.6.9.1 Overview
7.6.9.2 Other Anticholinergics: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.7 Intravesical Instillation
7.7.1 Overview
7.7.2 Intravesical Instillation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8. APAC Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type
8.1 Overview
8.2 APAC Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
8.3 Idiopathic Overactive Bladder
8.3.1 Overview
8.3.2 Idiopathic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Neurogenic Overactive Bladder
8.4.1 Overview
8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis
9.1 Overview
9.1.1 APAC: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
9.1.1.1 China: overactive bladder treatment Market - Revenue and Forecast to 2028 (USD Million)
9.1.1.1.1 China: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.2 China: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
9.1.1.1.2.1 China: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.1.1.2.2 China Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.1.1.3 China: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
9.1.1.2 Japan: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.1 Japan: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.2 Japan: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
9.1.1.2.2.1 Japan: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.1.2.2.2 Japan Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.1.2.3 Japan: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
9.1.1.3 India: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
9.1.1.3.1 India: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.2 India: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
9.1.1.3.2.1 India: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.1.3.2.2 India Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.1.3.3 India: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
9.1.1.4 South Korea: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.4.1 South Korea: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.4.2 South Korea: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
9.1.1.4.2.1 South Korea: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.1.4.2.2 South Korea Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.1.4.3 South Korea: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
9.1.1.5 Australia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.5.1 Australia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.5.2 Australia: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
9.1.1.5.2.1 Australia: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.1.5.2.2 Australia Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.1.5.3 Australia: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
9.1.1.6 Rest of APAC: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.6.1 Rest of APAC: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.6.2 Rest of APAC: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
9.1.1.6.2.1 Rest of APAC: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.1.6.2.2 Rest of APAC Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.1.6.3 Rest of APAC: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
10. Overactive Bladder Treatment Market- Industry Landscape
10.1 Overview
10.2 Organic Developments
10.2.1 Overview
11. Company Profiles
11.1 Alembic Pharmaceuticals Limited
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Astellas Pharma Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 AbbVie Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Teva Pharmaceutical Industries Ltd
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Endo Pharmaceuticals Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co. Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Medtronic Plc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Pfizer Inc
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms
Table 1. China Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 2. China Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 3. China Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 4. China Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 5. Japan Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 7. Japan Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 8. Japan Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 9. India Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 10. India Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 11. India Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 12. India Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 13. South Korea Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 14. South Korea Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 15. South Korea Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 16. South Korea Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 17. Australia Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 18. Australia Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 19. Australia Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 20. Australia Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of APAC Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of APAC Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of APAC Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of APAC Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 25. Organic Developments Done by Companies
Table 26. Glossary of Terms
Figure 1. APAC Overactive Bladder Treatment Market Segmentation
Figure 2. APAC Overactive Bladder Treatment Market Segmentation, By Country
Figure 3. APAC Overactive Bladder Treatment Market Overview
Figure 4. Mirabegron Segment Held Largest Share by Pharmacotherapy in APAC Overactive Bladder Treatment market
Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. APAC: PEST Analysis
Figure 8. APAC Overactive Bladder Treatment Market: Impact Analysis of Driver and Restraints
Figure 9. APAC Overactive Bladder Treatment Market - Revenue Forecast and Analysis - 2020- 2028
Figure 10. APAC Overactive Bladder Treatment Market, by Pharmacotherapy 2021 & 2028 (%)
Figure 11. Mirabegron: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Botox: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Neurostimulation: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Transcutaneous Sacral Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 15. Transcutaneous Tibial Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ MN)
Figure 16. Percutaneous Posterior Tibial Nerve: APAC Overactive Bladder Stimulation Market Revenue and Forecasts To 2028 (US$ MN)
Figure 17. Others: APAC Overactive Bladder Market Revenue and Forecasts To 2028 (US$ MN)
Figure 18. Anticholinergics: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Solifenacin: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Oxybutynin: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Fesoterodine: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Darifenacin: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Tolterodine: APAC Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Trospium: APAC Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Other Anticholinergics: APAC Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Intravesical Instillation: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. APAC Overactive Bladder Treatment Market, by Disease Type 2021 & 2028 (%)
Figure 28. Idiopathic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Neurogenic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 30. APAC: Overactive Bladder Treatment Market, by Key Country - Revenue (2021) (US$ Million)
Figure 31. China: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Japan: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. India: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. South Korea: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. Australia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Rest of APAC: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Companies Mentioned
- AbbVie Inc
- Alembic Pharmaceuticals Limited
- Astellas Pharma Inc
- Endo PHARMACEUTICALS Inc.
- Hisamitsu Pharmaceutical Co., Inc.
- Medtronic Plc
- Pfizer Inc
- Teva PHARMACEUTICAL Industries Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | January 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 871.48 Million |
| Forecasted Market Value ( USD | $ 1082.25 Million |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 8 |
